Workflow
左心室辅助装置
icon
Search documents
进入创新通道!经导管植入式无导线心脏起搏器
思宇MedTech· 2025-06-05 18:08
思宇年度活动回顾: 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开: 2025年6月12日,首届全球医美科技大会 2025年7月17日,第二届全球医疗科技大会 2025年9月4-5日,第三届全球手术机器人大会 2025年6月3日,NMPA公布了创新医疗器械特别审查申请审查结果公示(2025年第5号),有 6款产品 进入创新通道。 其中包括, 西安敦博医疗器械有限公司 (简称" 敦博医疗 ")申请的 经导管植入式无导线心脏起搏器 。 敦博医疗创始人 何玉平 曾经表示: "无导线心脏起搏器作为起搏器最新一代技术,具有 更小体积、更便 捷、更安全 的优点,在心脏病的治疗中应用前景广阔。敦博医疗通过 自主研发芯片 ,实现了无导线心脏 起搏器关键技术的突破,不仅赶超了世界最高水平,且又向前多跨了一小步。在技术层面,进一步缩小了 起搏器的体积,大幅度降低了起搏器静态功率,并延长了起搏器的使用寿命,从而使无导线心脏起搏器在 临床中的应用变得更便捷和安全。" # 关于心脏再同步治疗(CRT) 心力衰竭 是一种全球性健康问题,影响着数以千万计的人群。 它是由于 各类心脏疾病导致心脏泵血能力 下降,不能 ...
回顾:首届全球心血管大会 | GCC2025
思宇MedTech· 2025-05-20 09:26
Core Viewpoint - The Global Cardiovascular Conference 2025 highlighted the latest advancements in cardiovascular technology innovation, emphasizing the importance of clinical-driven and industry collaboration for the growth of the cardiovascular device sector [1][10][71]. Group 1: Conference Overview - The conference was held on May 15, 2025, in Beijing, gathering over 600 professionals from clinical, research, industry, and investment sectors to discuss cardiovascular technology innovation and enterprise growth paths [1]. - The event featured the release of the "2025 Global Cardiovascular Innovation Annual White Paper," which presented the latest development patterns in the cardiovascular device market [10]. Group 2: Awards and Recognition - The conference awarded three major prizes: the "2025 Global Cardiovascular Technology Innovation Award," the "2025 Global Cardiovascular Clinical Application Award," and the "2025 Global Cardiovascular International Cooperation Award," recognizing outstanding contributions in technology breakthroughs and clinical applications [13][14]. - A total of 10 companies received the technology innovation award, while 7 companies were recognized for clinical applications, and 4 units received the international cooperation award [13][14]. Group 3: Policy and Support - The Haidian District government expressed strong support for cardiovascular medical technology as a strategic direction, aiming to promote the market reach of cardiovascular devices [5]. - Beijing's policy support will focus on enhancing "clinical-driven + industry collaboration" mechanisms to facilitate innovation and results transformation in the cardiovascular field [7]. Group 4: Clinical and Engineering Collaboration - Experts emphasized the need for deep collaboration between clinical practitioners and engineers to address clinical pain points and drive innovation in cardiovascular devices [17][23]. - The conference featured discussions on the evolution of coronary intervention techniques and the importance of integrating clinical needs into device development [20][23]. Group 5: Investment Insights - The cardiovascular device sector is entering a critical window where companies with original technologies and systematic compliance capabilities will be highly valued by capital and policy [50]. - Early-stage companies face challenges in selecting the right market segments, while mid-stage companies must navigate structural adjustments and new payment logic to survive [51]. Group 6: Market Education and Product Strategy - The importance of educating the market on new surgical techniques and fostering collaboration between clinicians and engineers was highlighted as essential for successful product adoption [69]. - Companies are encouraged to build a product matrix that supports long-term growth and resilience against market fluctuations [63]. Group 7: Future Outlook - The conference served as a starting point for further discussions on how to leverage original technologies and promote Chinese innovations on the global stage [71][72]. - The cardiovascular industry is poised for transformation, driven by policy changes and technological advancements, necessitating a focus on clinical value and collaborative innovation [71].